Sara Lopez-Tarruella | OMICS International
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Sara Lopez-Tarruella

Sara Lopez-Tarruella
Attending physician
Gregorio Marañon Hospital (Madrid)


I got my MD degree at Universidad Autónoma (Madrid, 2001) and after completing my residency program at Hospital Clínico San Carlos (Universidad Complutense, Madrid) I obtained board certification in Medical Oncology (2006). After specializing I began my postdoctoral fellowship in basic/translational research at Baylor College of Medicine in the Breast Center (Houston), I was focused in the field of molecular mechanisms of breast cancer resistance to endocrine therapy under the direction of Dr. CK. Osborne and Dr. R Schiff. Back in Spain, I obtained my PhD degree at Universidad Complutense (Madrid), studying de novo metastatic breast cancer prognostic factors in the GEICAM Alamo project I-II under the direction of Prof. M Martin & Prof. E Diaz-Rubio (2009). From 2007, I have had three appointments at university hospitals in the country and I am currently working as an attending physician at Gregorio Marañon Hospital (Madrid). I work in the breast cancer and phase I trial units at HGUGM, contributing as co-investigator in several clinical and translational research trials and as full-member of scientific societies and research cooperative groups (GEICAM, SEOM…). 

Research Interest

My main interests are focused on one hand on breast cancer prevention and treatment, specially in the triple negative subtype, the neoadjuvant model and early-phase new drug development, and on the other hand on translational research, PDX models and liquid biopsy.

Global Speakers in the subject

Global Experts in the subject